NEMO: Binimetinib Shows Promising Activity in NRAS-Mutant Cutaneous Melanoma

June 3-7, 2016; Chicago, Illinois
Binimetinib significantly improved PFS and response rates in NRAS-mutant melanoma, particularly in patients who received prior immunotherapy.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.75 MB
Released: June 10, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

On-demand webcast describing how to incorporate new data into current treatment algorithms in melanoma presented by Clinical Care Options (CCO)

Jeffrey S. Weber, MD, PhD
Program Director
Allison Betof Warner, MD, PhD Hussein Tawbi, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 29, 2021 Expired: September 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue